Abstracts

Filters

Clear Filters
All Days Sun, Sep 27 Mon, Sep 28 Tue, Sep 29 Wed, Sep 30

Monday, September 28

10:55 AM - 11:05 AM ET

204 - Tislelizumab plus P-GemOx-14 and Radiotherapy for Early-Stage High-Risk Extranodal NK/T-Cell Lymphoma: A Multicenter, Single-Arm, Phase 2 Trial
Speaker: Qi, Shunan, MD, MB - Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing
11:05 AM - 11:15 AM ET

167 - Comparison of Treatment Outcome Between Short-Course Total Neoadjuvant Therapy vs. Neoadjuvant Long-Course Chemoradiotherapy Alone in Locally Advanced Rectal Adenocarcinoma: A Phase III Randomized Controlled Trial
Speaker: Barik, Sandip Kumar, MD, MBBS - King George's Medical University, Lucknow, Uttar Prad
11:05 AM - 11:15 AM ET

174 - Secondary Immunological Analysis of a Prospective Trial in Patients with Recurrent Head and Neck Malignancies
Speaker: Unnikrishnan, Soumya, MD, MS - Winship Cancer Institute of Emory University, Atlanta, GA
11:05 AM - 11:15 AM ET

179 - Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT): Long-Term Outcomes
Speaker: Oska, Caroline, MD - Montefiore Einstein Comprehensive Cancer Center, Bronx, NY
11:05 AM - 11:15 AM ET

185 - Repeat Catheter Ablation vs. Stereotactic Arrhythmia Radioablation for Recurrent Ventricular Tachycardia in Structural Heart Disease: The STAR-VT-2020 Randomized Trial
Speaker: Cvek, Jakub, MD, PhD - University Hospital Ostrava, Ostrava, Ceská republika
11:05 AM - 11:15 AM ET

192 - Estimating Neurocognitive Failure in the Presence of Competing Mortality: Kaplan-Meier and Competing-Risk Analyses from NRG CC001
Speaker: Zarinshenas, Reza, MD - University of Maryland Radiation Oncology, Baltimore, MD
11:05 AM - 11:15 AM ET

199 - Early Adaptive Interventions in Lung Cancer: Leveraging Fusion of Longitudinal CBCT Trajectories and Clinical Variables for Robust Survival Prediction
Speaker: Choi, Wookjin, PhD - Thomas Jefferson University, Philadelphia, PA
11:05 AM - 11:15 AM ET

205 - 30Gy vs 40Gy Consolidative Radiotherapy for Limited-Stage Diffuse Large B cell Lymphoma Achieving Complete Remission after Chemotherapy: A Randomized, Open-Label, Non-Inferiority, Multicenter Phase 3 Clinical Trial
Speaker: Qi, Shunan, MD, MB - Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing
11:15 AM - 11:25 AM ET

168 - Immunotherapy Based Total Neoadjuvant Therapy with or without Short-Course Radiotherapy for Locally Advanced Rectal Cancer: Initial Results of TORCH-iTNT
Speaker: Xia, Fan, MD, PhD - Fudan University Shanghai Cancer Center, Shanghai, Shanghai
11:15 AM - 11:25 AM ET

175 - Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: 3-Year Follow-Up of the INSIGHT Study
Speaker: Ou, Xiaomin, MD - Fudan University Shanghai Cancer Center, Shanghai, Shanghai
11:15 AM - 11:25 AM ET

180 - Firmonertinib plus Radiotherapy vs. Concurrent Chemoradiotherapy followed by Firmonertinib Consolidation in Unresectable Stage III <em>EGFR</em>-mutant NSCLC: A Randomized Phase 2 Trial
Speaker: Wang, Linlin, MD, PhD - Shandong Cancer Hospital and Institute, Jinan
11:15 AM - 11:25 AM ET

186 - Quality of Life and Toxicities Following Whole-Palm vs. Involved-Field Radiotherapy for Dupuytren's Disease: A Sub-Study from a Randomized Trial
Speaker: Martin, Jarad, MB, ChB, PhD, DMed(Research) BSc FRANZCR GAustMS - Calvary Mater Newcastle Hospital, Newcastle, NSW